Meningococcal C conjugate vaccine: The experience in England and Wales

被引：129

作者：

Campbell, Helen ^{[1
]}

Borrow, Ray ^{[2
]}

Salisbury, David ^{[3
]}

Miller, Elizabeth ^{[1
]}

机构：

[1] Hlth Protect Agcy Ctr Infect, Immunisat Hepatitis & Blood Safety Dept, London NW9 5EQ, England

[2] Manchester Royal Infirm, Hlth Protect Agcy NW, Meningococcal Reference Unit, Manchester M13 9WL, Lancs, England

[3] Dept Hlth, London SE1 6TE, England

来源：

VACCINE | 2009年 / 27卷

关键词：

Meningococcal serogroup C disease; Meningococcal C conjugate vaccine; Surveillance; INFLUENZAE TYPE-B; IMMUNOLOGICAL MEMORY; NEISSERIA-MENINGITIDIS; UNITED-KINGDOM; CHANGING EPIDEMIOLOGY; IMMUNIZATION CAMPAIGN; MASS IMMUNIZATION; VIRULENT CLONE; NO EVIDENCE; UK INFANTS;

D O I：

10.1016/j.vaccine.2009.04.067

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Meningococcal C conjugate vaccine was introduced in the UK in November 1999 together with a comprehensive meningococcal surveillance strategy to support and inform the vaccine programme. These surveillance data have provided important information on the long-term effectiveness of the programme, through direct and indirect protection, and on the prevalent serotypes and serosubtypes causing invasive meningococcal infection subsequent to vaccine introduction. The MCC immunization programme has been extremely successful in controlling serogroup C disease and continues to be evaluated. The aim of this paper is to review the experiences in England and Wales over the past 9 years. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：B20 / B29

页数：10

共 88 条

[1] Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome
Abeyagunawardena, AS
Goldblatt, D
Andrews, N
Trompeter, RS
[J]. LANCET, 2003, 362 (9382) : 449 - 450
[2] Post-licensure safety of the meningococcal group C conjugate vaccine
Andrews, Nick
Stowe, Julia
Miller, Elizabeth
Taylor, Brent
[J]. HUMAN VACCINES, 2007, 3 (02): : 59 - 63
[3] EMERGENCE OF A VIRULENT CLONE OF NEISSERIA-MENINGITIDIS SEROTYPE-2A THAT IS ASSOCIATED WITH MENINGOCOCCAL GROUP-C DISEASE IN CANADA
ASHTON, FE
RYAN, JA
BORCZYK, A
CAUGANT, DA
MANCINO, L
HUANG, D
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1991, 29 (11) : 2489 - 2493
[4] Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom
Auckland, Cressida
Gray, Stephen
Borrow, Ray
Andrews, Nick
Goldblatt, David
Ramsay, Mary
Miller, Elizabeth
[J]. JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (12) : 1745 - 1752
[5] THE IMPACT OF CONJUGATE VACCINE ON CARRIAGE OF HAEMOPHILUS-INFLUENZAE TYPE-B
BARBOUR, ML
MAYONWHITE, RT
COLES, C
CROOK, DWM
MOXON, ER
[J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (01) : 93 - 98
[6] Increasing incidence of meningococcal disease in Spain associated with a new variant of serogroup C
S. Berrón
L. De La Fuente
E. Martín
J. A. Vázquez
[J]. European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17 (2) : 85 - 89
[7] The Impact of Childhood Meningococcal Serogroup C Conjugate Vaccine Programs in Canada
Bettinger, Julie A.
Scheifele, David W.
Le Saux, Nicole
Halperin, Scott A.
Vaudry, Wendy
Tsang, Raymond
[J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (03) : 220 - 224
[8] Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster
Booy, R
Heath, PT
Slack, MPE
Begg, N
Moxon, ER
[J]. LANCET, 1997, 349 (9060) : 1197 - 1202
[9] Impact of meningococcal C conjugate vaccine use in Australia
Booy, Robert
Jelfs, Jane
El Bashir, Haitham
Nissen, Michael D.
[J]. MEDICAL JOURNAL OF AUSTRALIA, 2007, 186 (03) : 108 - 109
[10] Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom
Borrow, R
Goldblatt, D
Andrews, N
Southern, J
Ashton, L
Deane, S
Morris, R
Cartwright, K
Miller, E
[J]. JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (09) : 1353 - 1357

← 1 2 3 4 5 6 7 8 9 →